1. Home
  2. MCB vs XERS Comparison

MCB vs XERS Comparison

Compare MCB & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metropolitan Bank Holding Corp.

MCB

Metropolitan Bank Holding Corp.

HOLD

Current Price

$98.01

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$8.56

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCB
XERS
Founded
1999
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
MCB
XERS
Price
$98.01
$8.56
Analyst Decision
Buy
Buy
Analyst Count
3
6
Target Price
$98.67
$10.83
AVG Volume (30 Days)
133.7K
2.4M
Earning Date
04-21-2026
05-07-2026
Dividend Yield
1.13%
N/A
EPS Growth
11.64
100.00
EPS
2.92
0.01
Revenue
$11,053,000.00
$49,590,000.00
Revenue This Year
$37.22
$34.37
Revenue Next Year
$14.75
$22.86
P/E Ratio
$32.89
$867.00
Revenue Growth
N/A
142.67
52 Week Low
$64.66
$4.87
52 Week High
$102.04
$10.08

Technical Indicators

Market Signals
Indicator
MCB
XERS
Relative Strength Index (RSI) 56.25 76.13
Support Level $86.38 $6.86
Resistance Level N/A $10.08
Average True Range (ATR) 2.53 0.32
MACD -0.26 0.11
Stochastic Oscillator 55.86 77.31

Price Performance

Historical Comparison
MCB
XERS

About MCB Metropolitan Bank Holding Corp.

Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: